A recent 2-year carcinogenicity/toxicology study determined that phenolphthalein (PHTH) is a multisite carcinogen in both mice and rats at all doses evaluated. In response to this finding the metabolism and disposition of PHTH has been evaluated in both F344 rats and B6C3F1 mice at a single oral dose of 800 mg/kg. This dose fell within the range previously found to be carcinogenic in rats and mice. Studies were also performed using 1 and 50 mg/kg doses. At 800 mg/kg recovery of [ 14 C]PHTH after 72 h was near 100% in females but closer to 75% in males. Radioactivity was primarily recovered in the feces in rats (>90%), while mice excreted 30-40% of administered activity in the urine. There was no significant retention of radioactivity in tissues by 72 h and no significant accumulation of radioactivity in any tissue at any time point Covalent binding to protein in target tissues, bone marrow and ovary, was at or less than the pmol/mg protein range. The major metabolite was PHTH glucuronide. Three minor metabolites were detected. A sulfate conjugate and and a hydroxylated metabolite were identified by comparison of retention times and 'H NMR and/or mass spectra with synthetic standards. A diglucuronide conjugate was tentatively identified. Biliary elimination was extensive in rats (35% of dose within 6 h); the only product detected in bile was phenolphthalein glucuronide.
A recent 2-year carcinogenicity/toxicology study determined that phenolphthalein (PHTH) is a multisite carcinogen in both mice and rats at all doses evaluated. In response to this finding the metabolism and disposition of PHTH has been evaluated in both F344 rats and B6C3F1 mice at a single oral dose of 800 mg/kg. This dose fell within the range previously found to be carcinogenic in rats and mice. Studies were also performed using 1 and 50 mg/kg doses. At 800 mg/kg recovery of [ 14 C]PHTH after 72 h was near 100% in females but closer to 75% in males. Radioactivity was primarily recovered in the feces in rats (>90%), while mice excreted 30-40% of administered activity in the urine. There was no significant retention of radioactivity in tissues by 72 h and no significant accumulation of radioactivity in any tissue at any time point Covalent binding to protein in target tissues, bone marrow and ovary, was at or less than the pmol/mg protein range. The major metabolite was PHTH glucuronide. Three minor metabolites were detected. A sulfate conjugate and and a hydroxylated metabolite were identified by comparison of retention times and 'H NMR and/or mass spectra with synthetic standards. A diglucuronide conjugate was tentatively identified. Biliary elimination was extensive in rats (35% of dose within 6 h); the only product detected in bile was phenolphthalein glucuronide.
Phenolphthalein (3,3-bis(4-hydroxyphenyl)-l-(3H)-isobenzofuranone, PHTH) is the active ingredient in several over-thecounter laxatives and has been in use since 1902 (Dunnick and Hailey, 1996; NTP, 1996; Vissek et al, 1956) . Although long believed to be relatively safe, increasing abuse of laxatives for dieting purposes (Bo-Linn et al, 1983) and a lack of toxicity data led to an NTP evaluation of the toxicity of this compound. In 13-week toxicity studies, toxic effects were seen only in animals that received doses far in excess of the human therapeutic dose (Dietz et al, 1992) . A 2-year carcinogenicity/ toxicity study determined that PHTH is a multisite carcinogen in both rats and mice at all doses evaluated (Dunnick and Hailey, 1996; NTP, 1996) . In mice there were increased incidences of malignant lymphoma of thymic origin, histiocytic sarcomas, observed most often in liver, and benign sex cord stromal tumors of the ovaries, as well as non-neoplastic effects on the thymus, adrenal, kidney, ovary, and testis. In rats there were increased incidences of adrenal and kidney tumors, with renal effects being the major non-neoplastic toxicity. The incidence of tumors was the same at all doses, possibly because blood levels of free phenolphthalein did not increase with dose.
The wide range of carcinogenic and toxic effects of PHTH may be the result of the combination of its estrogenicity (Ravdin et al, 1987) , its clastogenicity (Witt et al, 1995) , and its ability to generate free radicals (Sipe et al, 1997) . The metabolism and disposition of PHTH may also play a role. In previous disposition studies in mice, no accumulation of radioactivity was detected in any of the target tissues that were examined (Vissek et al, 1956) . However, the doses in these studies were very low, many of the target tissues were not examined, and disposition in the rat has not been previously reported. As a result there is the possibility that an accumulation of PHTH in a target tissue may occur or a reactive metabolite may be produced at high doses. Biotransformation of PHTH is primarily by conjugation with glucuronic acid, but a small amount of sulfation may also occur (Vissek et al, 1956; Wilhelm et al, 1992; Parker et al, 1980; Colburn et al, 1979; Gustafson and Benet, 1974) . PHTH is often used as a model substrate in studies of glucuronidation (Sund and Lauterbach, 1986; Yang and Carlson, 1991) .
In this study, the metabolism and disposition of phenolphthalein were examined in male and female rats and mice. Both carcinogenic and therapeutic-equivalent doses were used. Females were emphasized because the ovarian tumors seen in the 2-year study were deemed to be of the greatest toxicological concern. radiochemical used in these studies was of greater than 99% radiochemical purity.
MATERIALS AND METHODS

Chemicals
Apparatus. 'H NMR spectra were determined on a Varian Unity Plus (Palo Alto, CA) 500-MHz NMR spectrometer. The chemical shifts are reported relative to tetramethylsilane as the external standard.
FAB mass spectra were obtained on a VG ZAB-4F (VG Analytical, Manchester, UK) with glycerol as the matrix unless otherwise noted.
The HPLC system employed two Waters Associates (Milford, MA) pumps and an automated gradient controller. A Beckman Model 163 Variable Wavelength detector was used for UV detection and a Radiomatic (Tampa, FL) Flo-One f) radiochemical detector was used for quantitation of peaks. Separation was achieved on a C18, 5.0-mm, Rainin (Rainin Instrument Co., Wobum, MA) Microsorb column (4.6 X 250 mm). The HPLC assay is a modification of that reported by Wilhelm etai. (1992) and consisted of a linear gradient from 85% 50 mM sodium phosphate (pH 4.0)/15% acetonitrile to 100% acetonitrile from 3 to 17 min. The flow rate was set at 1.5 ml/min. Syntheses. Phenolphthalein sulfate was prepared by reacting phenolphthalein (32 mg, 0.1 mmol) with 159 mg (0.1 mmol) SOj/pyridine in 1 ml of dry ditnethylformamide, under a N 2 atmosphere, starting at 0°C and wanning to room temperature over a 3-h period. The monosulfate was isolated from the DMF solution by HPLC using a Rainin C 18 column with 65% water/35% acetonitrile as eluant at 1.5 ml/min: 'H NMR (dimethyl sulfoxide-d,^ 6.74 (d, J = 8.6 Hz, 2H) and 7.03 (d, J = 8.6 Hz, 2H) unsulfated phenol; 7.14 (d, J = 8.7 Hz, 2H) and 7.20 (d, / = 8.7 Hz, 2H) sulfated phenol; 7.64, (m, 1H), 7.8 (m, 2H), and 7.89 (d, J = 7.5 Hz, 1H) isobenzofuranone. The negative-ion FAB mass spectrum contained a pseudomolecular ion at mle 397 (M-H+).
Hydroxyphenolphthalein (3-{4-hydroxyphenyl)-3-(3,4-dihydroxyphenyl)-l-(3H>isobenzofuranone) was prepared by oxidation of phenolphthalein with dimethyldioxirane by modifying a method described by Corey and Ward (1986) for epoxidation of or, 3-unsaluraled acids. Phenolphthalein (1 g, 3.1 mmol) and NaHCO 3 (0.88 g) were slurried in 4.6 ml of water and 4.6 ml of acetone. The mixture was cooled to ca. 20°C and 1.73 g of Oxone (5.6 mmol potassium monopersulfate) dissolved in 6.6 ml of 0.4 mM disodium EDTA was added dropwise over an hour while maintaining the temperature at 20-22°C. After 2 additional h, the mixture was extracted with ethyl acetate, the organic solution was dried (MgSO 4 ) and concentrated, and the residue was 58.0 + 6.6 82.7 ± 5.0 53.1 ±28.5 11.5 ± 1.5 7.6 + 1.1 9.00 ± 3.24 20.1 ± 1.6 13.2 ± 1.8 33.7 + 20.9 21.9 ± 1. Animals. All animal procedures were approved by the Institutional Animal Care and Use Committee. Male and female F344 rats and B6C3F1 mice (Taconic, Gcrmantown, NY) were allowed to acclimatize for at least 5 days following arrival. All animals were 11 weeks old upon arrival.
Treatments. In most cases, animals were dosed by gavage (4 ml/kg for rats; 10 ml/kg for mice) with [ 14 qPHTH (5.0 jiCi/mouse and 15.0 fiCi/rat) in water/ethanol/emulphor (8/1/1), at doses of 50 and 800 mg/kg. There were three animals/group except where otherwise noted. Three female mice were given PHTH by iv bolus and three were given PHTH by gavage at 1 mg/kg. For the determination of metabolites in bone marrow and ovaries, 12 female mice were given 1 mg of PHTH (roughly 50 mg/kg) and 20 mCi of [ M C]PHTH orally.
Collection of samples. Immediately after dosing, the animals were held in Jencons Metabowl (Hemel Hempstead, Hertfordshire, England) glass metabolism cages for the separate collection of urine and feces. The animals were housed one per cage for 2, 8, 24, 48, or 72 h at which time the animals were euthanized and tissues collected. Tissues were frozen and stored at -20°C.
Sample preparation. Urine was centrifuged at 1000 rpm for 10 min to remove paniculate material and injected directly on the HPLC. Feces were homogenized in sodium acetate buffer (pH 6.8, 100 mM) using a Kinematica Gmbh polytron (Brinkman Instruments, Westbury, NY). One milliliter of fecal " Mean ± standard error, N = 3. * Significantly (p £ 0.05) different from males at the same dose.
homogenate was precipitated with 3.0 ml of methanol, vigorously vortexed, refrigerated overnight, and centrifuged at 1000 rpm for 10 min. The supernatant was then passed through a C18 Sep Pak. Total radioactivity in urine samples was determined by directly counting aliquots of urine. Fecal homogenates were dried and then oxidized in a Packard Model 306 Oxidizer (Downers Grove, IL) for determination of total fecal radioactivity. Triplicate weighed aliquots of blood, liver, kidney, muscle, adrenal, fat, testis, ovary, thymus, thyroid, and bone marrow were oxidized to determine tissue distribution.
Tissue metabolites. Remaining blood and liver from the 2-h disposition animals was homogenized in Tris (50 mM, pH 7.40) at 1 g of tissue/3 ml of buffer. Methanol (9 ml) was added to 3 ml of homogenate, which was then centrifuged at 2500 rpm for 20 min. The pellets were resuspended in 3 ml of Tris and the procedure was repeated. Supematants were concentrated and passed through a 0.5-/im filter prior to HPLC analysis. Liver pellets were processed for covalent protein adduct analysis.
In addition, liver, ovaries, and bone marrow were collected from an additional group of 12 mice receiving higher specific activity [ U C]PHTH. Liver was treated as described above. Ovaries harvested from each of three groups of 4 animals were placed into 2 ml of Tris and homogenized Methanol (10 ml) was added and the homogenate centrifuged at 2500 rpm for 20 min. Femurs and humeri were dissected out, pooled into three groups derived from 4 animals each, split with a scalpel to expose die marrow, and placed into 2 ml of Tris. The bones were crushed with a spatula to extract the marrow into the buffer. The resulting pink liquid was poured off and 10 ml of methanol added to the bone fragments, which were then further crushed. The methanol was removed and added to the original marrow extract, which was then centrifuged at 2500 rpm for 20 min. Liver, ovary, and marrow supematants were treated as previously described and the pellets used for covalent protein adduct determination.
Bile duct cannuiation. Female F344 rats (Taconic) were anesthetized with pentobarbital (50 mg/kg, ip). Bile ducts were exposed by midline incision, isolated, and cannulated with PE-10 tubing. Once the bile duct was cannulated, the animals were dosed with [ M C]PHTH (5.0 mCi/rat in water/ethanol/emulphor (8/1/1) by direct injection into the exposed stomachs using a 25-gauge needle. The volume of injection was 4 ml/kg and the dose was 800 mg/kg. The animals were then closed for the collection of bile. Anesthesia and hydration were maintained throughout the collection period; body temperature was maintained using a heating pad. The bile was collected in vials for 30-min intervals for 6 h. The amount of bile excreted per time point was weighed and duplicate 25-ml aliquots were counted by LSC. The remaining bile was diluted with two parts methanol and analyzed by HPLC for determination of the biliary metabolite profile.
Covalent protein adducts.
Protein pellets were washed in a series of solvents (5 ml/wash) and centrifuged at 2000 rpm. The order of the washes was 80% methanol X3, 0.4 M TCA XI, 3:1 ethanokether XI, and 80% methanol X1. This sequence was repeated until the total activity in the supernatant was less than 3X background. The pellets were then solubilized, the protein content was determined, and aliquots were counted by LSC.
Metabolite identification. Metabolites were initially identified by cochromatography with synthetic standards where available. Proton NMR provided verification of structural identity. In some cases, incubation with glucuronidase/sulfatase provided additional information. Conjugates were identified by the action of Type DC 0-glucuronidase or Type VII sulfatase and saccharolactone (all three from Sigma) on urine or fecal homogenates. Incubations with glucuronidase or sulfatase were performed in sodium acetate buffer (100 mM, pH 6.5) at 37°C for 24 h.
Statistics. Statistical comparisons were made using an unpaired Student's Mest (p £ 0.05). Figure 1 is a metabolism scheme for phenolphthalein in rats and mice based on this study. PHTH and PHTH-glucuronide were initially identified by cochromatography with authentic standards. Comparison of 'H NMR spectra on isolated and authentic PHTH and PHTH glucuronide revealed no differences. Phenolphthalein diglucuronide may also have been present in male mouse urine. A peak in the HPLC, eluting before PHTH glucuronide, in urine from male mice was diminished by /3-glucuronidase incubation and was assumed to be a diglucuronide. Phenolphthalein sulfate was identified by comparison of the retention time, J H NMR, and mass spectrum of the isolated material with a synthetic standard. Hydroxyphenolphthalein (PHTH-OH) was identified by comparison of the 'H NMR spectrum of isolated material with that of a synthetic standard (Fig. 2) . Hydroxyphenolphthalein was obtained from dimethyldioxirane oxidation of phenolphthalein. Demonstration that the product of oxidation was a catechol and not the resorcinol analog was provided by the formation of a cyclic boronate ester of the synthetic material.
RESULTS
Metabolite identification.
Recovery. Total recovery of administered radioactivity was 72.1 ± 3.2 and 92.8 ± 0.2% in male and female mice, respectively, 72 h after oral administration of [ 14 C]PHTH at 800 mg/kg. Recovery was 79.6 ± 4.6 and 101.6 ± 3.6% in male and female rats, respectively, under the same conditions. Total recoveries were clearly higher in females. Expired air " Mean ± standard error, N = 3. * Significantly different (p =3 0.05) from female F344 rats (Table 1) . c ND, not detected. was not analyzed because no radioactivity was eliminated by this route in a previous investigation (Vissek et at, 1956) . The cumulative radioactivity recovered in urine and feces is shown in Figs. 3 and 4 . The results clearly indicate that mice eliminate more PHTH-derived products in urine than rats and that females eliminate more in the urine than males. In Fig. 5 the cumulative radioactivity recovered in urine is compared following iv and oral administration of PHTH to female mice. Total urinary recovery of administered radioactivity was 25% following iv administration and 18% following oral, suggest- ing that 72% of PHTH is absorbed following oral administration.
Tissue distribution. The concentration of PHTH-derived products in rat and mouse tissues is presented in Tables 1-3. In Table 1 , there is no evidence for bioaccumulation of products in any tissue; virtually all the radioactivity has been eliminated by 72 h. Phenolphthalein appears to be absorbed more slowly by rats than by mice as the highest tissue concentrations were highest at 8 h in rats compared to 2 h in mice. There is also no consistent indication that there is concentration of PHTHderived products in target tissues such as ovary, bone marrow, or adrenal tissue. The highest tissue concentration was found in rat ovary at 8 h following dosing. However, ovary was a target tissue in mice, not rats. The rat ovary value is driven by a very high concentration found in one animal of four in the group. The concentration of PHTH-derived radioactivity in rat ovary at other times was similar to that of other tissues. Liver and blood usually contained the greatest concentration of radioactivity. In Table 2 , the only sex-dependent difference detected in rats was that high-dose male adrenals contained significantly more radioactivity than female adrenals. In mice at the low dose, there was significantly more radioactivity in tissues from females than in tissues from males in every case except thyroid. The concentration of PHTH-derived radioactivity tended to be dose-proportional except for female mice where there was a lower concentration of PHTH-derived radioactivity in the high-dose tissues than would be predicted from the lowdose results. As was observed with females, there was no indication of bioaccumulation in tissues 72 h after dosing in males at the high dose (Table 3) . Tissue concentration of radioactivity in male rats is generally higher than that in the corresponding tissue in females (Table 1) ; however, the difference reaches statistical significance only for liver, thyroid, and adrenal.
Urinary/fecal metabolites. Figure 6 shows radiochromatograms of PHTH and its metabolites in female mouse urine and feces after treatment with 800 mg/kg of [ 14 C]PHTH. The quantitation of the urinary and fecal metabolites of phenolphthalein in male and female rats and mice is shown in Table  4 . The glucuronide was generally the major product excreted in urine. The second most abundant product was PHTH, which may have been mostly derived from the breakdown of the glucuronide. The suspected diglucuronide was detected in male mouse urine only. PHTH-OH was detected in mouse urine and in male rat urine. At 1 mg/kg following both iv and oral administration to female mice, the same metabolites were detected in urine in about the same amounts as the 800 mg/kg dose (Table 5) . PHTH was the major product excreted in the feces (Table 4 ). The next most abundant product was phenolphthalein sulfate, and another metabolite, hydroxyphenolphthalein, was detected in mouse feces.
Biliary elimination. In female rats, bile flow was relatively constant over the 6 h that bile was collected (Fig. 7) . About 40% of the administered radioactivity was recovered in the bile within 6 h of dosing. HPLC analysis of the bile (data not shown) revealed only a single peak which corresponded to the glucuronide of PHTH.
Metabolites in tissues.
The metabolites found in 2-h blood samples are presented in Table 6 . The major product present was the monoglucuronide at 88% or more. PHTH-OH was detected in all mouse groups but never in rat blood. Metabolites in liver, bone marrow, and ovaries from animals dosed with high specific activity [
14 C]PHTH are described in Table 7 . Three products were detected and in all three tissues the Covalent protein adducts. Covalent protein adducts in liver tissue were detected in the pmol-nmol/mg range in PHTH-treated animals at 2 h postdosing (Table 8 ). Binding was always higher at the higher dose. In rats, binding was greater in males than in females. This was not always the case in mice. Covalent protein binding in target tissues such as bone marrow and ovary was much lower than in nontarget liver tissue (Table 7) .
DISCUSSION
Three doses were used in this study. A dose of 800 mg/kg was chosen because it fell within the range of doses found to be carcinogenic in both mice (ca. 300-1200 mg/kg/day) and rats (ca. 400-1200 mg/kg/day). The maximum human therapeutic dose is about 5 mg/kg, which falls between the two additional study doses chosen (1 and 50 mg/kg). These doses can also be expressed as milligrams per square meter of surface area, which is sometimes better for comparison between species. Expressed this way the human dose is 185 mg/m 2 , the doses used the disposition studies (1, 50, and 800 mg/kg) are 3, 150, and 2400 mg/m 2 in mice and 5.2, 260, and 4200 mg/m 2 in rats. Depending on the method used, the doses chosen in this 3.0 ± 1.6 6.0 ± 1.1 5.2 ± 2.8 -7.1 ±0.9 5.1 ± 2.6 6.2 ± 0.3 3.1 ± 1.6 study range from less than the human therapeutic dose up to the rodent carcinogenic range.
The feces are clearly the major route of elimination in rats. In mice, urinary and fecal elimination are both important. Urinary elimination is greater at 800 mg/kg than at 1 mg/kg (oral), indicating that absorption at the higher dose is not saturated, although another elimination route, possibly biliary elimination, may be. Even though significant excretion of PHTH glucuronide into bile occurs within 6 h after administration in rats, the glucuronide is not excreted in the feces. The parent compound is the major product present in the feces. This suggests that the glucuronide is readily hydrolyzed back to parent by bacteria in the gut and in rats intestinal /3-glucuronidase has been demonstrated to be very active on phenolphthalein glucuronide (Kenyon and Calabrese, 1993) .
A very limited number of pathways for metabolism of PHTH have been reported in the literature. Monoglucuronidation and possibly some sulfation are the only routes of metabolism reported in either urine or bile. For this reason, PHTH is often 4.3 ± 0.4 0.9 ± 0.9 0.8 ± 0.1 PHTH 7.9 ± 1.0 4.0 ± 2.0 1.7 ±0.2 selected as a model substrate for glucuronosyltransferases (Sund and Lauterbach, 1986; Yang and Carlson, 1991; Bolanowska and Gessner, 1978) . The results of this study suggest that the metabolism of phenolphthalein is a little more complicated than previously believed. A hydroxylated metabolite (PHTH-OH) and a probable diglucuronide were also detected. The relative importance of the diglucuronide may have been understated by the present study because it was fairly unstable. Even so, the toxicity/carcinogenicity of PHTH is not likely to be attributable to a diglucuronide. The hydroxylated metabolite might be linked to the toxicity/carcinogenicity of PHTH. This metabolite was seen in male rat urine and in mouse urine, feces, blood, and liver and in the target tissues, bone marrow and ovaries. If the hydroxylation occurs in extrahepatic tissues, a reactive epoxide precursor to the catechol or a quinone intermediate resulting from further oxidation of the catechol might be generated that could result in toxicity. However, such reactive intermediates would be expected to covalently bind to cellular proteins. No evidence of greater protein covalent binding was found in target versus nontarget tissues.
Phenolphthalein and its metabolic products did not concentrate in any tissue, including several target tissues. In the 2-year bioassay, PHTH caused neoplasia in the ovary of female mice, the hematopoietic system of male and female mice, the adrenal of male and female rats, and the kidney of male rats (Dunnick and Hailey, 1996) . The tissue to blood ratio of total radioactivity for ovary, bone marrow, thymus, spleen, adrenal, and kidney tended to be one or less, indicating that PHTH or its metabolites did not concentrate in these target tissues. By 72 h, only traces of radioactivity remained in any tissue, indicating lack of bioaccumulation. Covalent binding to protein in liver was dose dependent. However, binding in the target tissues, bone marrow and ovaries, in mice was much lower than in liver, a nontarget tissue.
The overall results in this study do not support the hypotheses that phenolphthalein-dependent tumorigenesis in rodents is dependent on metabolism to a non-ftee-radical-reactive intermediate or results from accumulation of products in target tissues. Small amounts of free phenolphthalein were detected in urine, feces, blood, liver, bone marrow, and ovaries. In the carcinogenicity study, the plasma level of free PHTH was the same at all carcinogenic doses (Dunnick and Hailey, 1996) . These results are consistent with proposals by other investigators that PHTH tumor induction is through generation of free radicals and/or the estrogenic activity of the parent compound (Ravdin et al., 1987; Sipe et al., 1997) . The hydroxyphenolphthalein, a catechol, could also be oxidized to a semiquinone free radical and may provide an additional source of radicalinduced toxicity/carcinogenicity.
